- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Recommends Gazyvaro for Treatment-Naive CLL Patients
The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.
Patients in England and Wales with chronic lymphocytic leukaemia are a step closer to getting access to Roche’s Gazyvaro (obinutuzumab) on the National Health Service, after cost regulators recommended the drug for routine use.
Gazyvaro is the first ‘type II’ anti-CD20 monoclonal antibody licensed for the treatment of CLL and is designed to attack blood cancers more aggressively than ‘type I’ treatments such as MabThera (rituximab).
Link to the complete article on PharmaTimes: http://bit.ly/1AfH0NA
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
